Home › Boston Strategics Corporation Initiates A Phase 1 Clinical Trial Of The Anti-Cancer Agent FF-10501' For FUJIFILM In Patients With Advanced Hematologic Malignancies
 

Keywords :   


Boston Strategics Corporation Initiates A Phase 1 Clinical Trial Of The Anti-Cancer Agent FF-10501' For FUJIFILM In Patients With Advanced Hematologic Malignancies

2014-09-03 11:37:54| drugdiscoveryonline Home Page

Boston Strategics Corporation (BSC), a primary global strategic drug development provider for FUJIFILM Pharmaceuticals U.S.A., Inc. (FPHU), has begun a Phase 1 clinical trial of FUJIFILM’s anti-cancer agent FF-10501 in the United States in patients with advanced hematologic malignancies, such as relapsed or refractory high-risk myelodysplastic syndromes (MDS)

Tags: with advanced corporation agent

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
18.05Eastern North Pacific Tropical Weather Outlook
18.05Atlantic Tropical Weather Outlook
18.05Producers to be paid grid premiums for AngusLink beef scores
18.05This Week in Agribusiness, May 18, 2024
18.05This Week in Agribusiness, May 18, 2024
18.05Unpaid carers being forced to repay 250m to DWP
18.05Weekly Recap: Hempel, Axalta, KANSAI HELIOS Top This Weeks Stories
18.05Eastern North Pacific Tropical Weather Outlook
More »